CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in March: 2018 Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 11:20 a.m.
- Generated 2017 revenue of $298 million , driven primarily by LINZESS ® (linaclotide) U.S. net sales of $701 million and expansion of LINZESS commercial margin to 61% - - On track to advance key pipeline candidates in 2018, including Phase III trials for IW-3718 and LINZESS and Phase II trials for
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2017 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2018 .
CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc ( NYSE : AGN) announced today that the companies have reached an agreement with wholly-owned subsidiaries of Sun Pharmaceutical Industries Ltd.
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 36 th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco .
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the initiation of STRONG-SCD, a Phase II clinical trial evaluating once-daily IW-1701, an orally administered soluble guanylate cyclase (sGC) stimulator, in
- Addition of IW-1973 to ongoing medical regimens used to treat diabetic patients with hypertension showed reductions in blood pressure, fasting plasma glucose, cholesterol and triglycerides, and improved endothelial function - -Data support advancement of IW-1973 for evaluation as a potential
- William Huyett Appointed to Chief Operating Officer - - Gina Consylman Promoted to Senior Vice President, Chief Financial Officer - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the appointment of William
- Ironwood revenue grew 31% to $87 million in 3Q 2017 over 3Q 2016 - - LINZESS ® (linaclotide) U.S. net sales increased 16% to $191 million and net profit increased 36% to $111 million in 3Q 2017 over 3Q 2016 - - Launched DUZALLO ® (lesinurad and allopurinol), a once-daily fixed-dose combination
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Credit Suisse 26 th Annual Healthcare Conference on Wednesday, November 8 th , 2017 at 10:25 a.m. Mountain Time / 12:25 p.m. Eastern Time at The Phoenician in Scottsdale,
You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.
Delicious
Digg
Facebook
LinkedIn
Twitter
